Table of Content

1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Key Questions Answered
1.4. Chapter Outlines


2. EXECUTIVE SUMMARY


3. INTRODUCTION
3.1. Overview of RAS Targeting Therapies
3.2. Approaches Used to Target Mutated RAS Gene
3.3. Historical Notable Developments
3.4. Prominent Gene Driver Related Mutations in RAS Mutated Cancers
3.5. Challenges and Future Perspectives Associated with Treatment of RAS Mutated Cancers


4. CURRENT MARKET LANDSCAPE
4.1. RAS Targeting Therapies: Pipeline Review
4.1.1. Analysis by Phase of Development
4.1.2. Analysis by Route of Administration
4.1.3. Analysis by Line of Treatment
4.1.4. Analysis by Type of Therapy
4.1.5. Analysis by Type of Molecule
4.1.6. Analysis by Target Gene
4.1.7. Analysis by Target Therapeutic Area
4.1.8. Analysis by Phase of Development and Leading Players
4.2. RAS Targeting Therapies: Developer Landscape
4.2.1. Analysis by Year of Establishment
4.2.2. Analysis by Company Size
4.2.3. Analysis by Location of Headquarters
4.2.4. Analysis by Geography

5. CLINICAL TRIALS AND ENDPOINT ANALYSIS
5.1. RAS Targeting Therapies: List of Clinical Trials
5.1.1. Analysis by Trial Status
5.1.2. Analysis by Trial Registration Year
5.1.3. Analysis by Type of Masking
5.1.4. Analysis by Type of Intervention Model
5.1.5. Analysis by Study Design
5.1.6. Analysis by Type of Sponsor
5.1.7. Most Active Players: Analysis by Number of Trials Registered
5.1.8. Analysis by Trial Registration Year and Geography
5.1.9. Analysis by Type of Target Indication
5.1.10. Analysis by Enrolled Patient Population
5.1.11. Analysis of Enrolled Patient Population by Geography
5.1.12. Analysis of Number of Clinical Trials by Geography

6. PRODUCT COMPETITIVENESS ANALYSIS
6.1. Product Competitiveness: North America
6.2. Product Competitiveness: Europe
6.3. Product Competitiveness: Asia-Pacific

7. COMPANY PROFILES
7.1. Amgen
7.1.1. Company Overview
7.1.2. Financial Information
7.1.3. Portfolio of RAS Targeting Therapies
7.1.4. Recent Developments and Future Outlook
7.2. GlobeImmune
7.2.1. Company Overview
7.2.2. Financial Information
7.2.3. Portfolio of RAS Targeting Therapies
7.2.4. Recent Developments and Future Outlook
7.3. Jacobio Pharmaceuticals
7.3.1. Company Overview
7.3.2. Financial Information
7.3.3. Portfolio of RAS Targeting Therapies
7.3.4. Recent Developments and Future Outlook
7.4. Mirati Therapeutics
7.4.1. Company Overview
7.4.2. Financial Information
7.4.3. Portfolio of RAS Targeting Therapies
7.4.4. Recent Developments and Future Outlook
7.5. Novartis
7.5.1. Company Overview
7.5.2. Financial Information
7.5.3. Portfolio of RAS Targeting Therapies
7.5.4. Recent Developments and Future Outlook
7.6. Onconova Therapeutics
7.6.1. Company Overview
7.6.2. Financial Information
7.6.3. Portfolio of RAS Targeting Therapies
7.6.4. Recent Developments and Future Outlook
7.7. Targovax
7.7.1. Company Overview
7.7.2. Financial Information
7.7.3. Portfolio of RAS Targeting Therapies
7.7.4. Recent Developments and Future Outlook
7.8. Verastem Oncology
7.8.1. Company Overview
7.8.2. Financial Information
7.8.3. Portfolio of RAS Targeting Therapies
7.8.4. Recent Developments and Future Outlook

8. PUBLICATION ANALYSIS
8.1. RAS Targeting Therapies: Recent Publications
8.1.1. Analysis by Year of Publication
8.1.2. Analysis by Type of Publication
8.1.3. Analysis by Study Objective
8.1.4. Analysis by Emerging Focus Areas
8.1.5. Analysis by Target Therapeutic Area
8.1.6. Analysis by Target Gene
8.1.7. Analysis by Target Indication
8.1.8. Analysis by Affiliation of First Author
8.1.9. Leading Players: Analysis by Number of Publications
8.1.10. Key Journals: Analysis by Number of Publications

9. PARTNERHSIPS AND COLLABORATIONS
9.1. RAS Targeting Therapies: List of Partnerships and Collaborations
9.1.1. Analysis by Year of Partnership
9.1.2. Analysis by Type of Partnership
9.1.3. Analysis by Type of Partner
9.1.4. Analysis by Type of Molecule
9.1.5. Most Active Players: Analysis by Number of Partnerships
9.1.6. Most Active Partners: Analysis by Number of Partnerships
9.1.7. Regional Analysis
9.1.8. Intercontinental and Intracontinental Agreements

10. FUNDING AND INVESTMENT ANALYSIS
10.1. RAS Targeting Therapies: Funding and Investments
10.1.1. Analysis by Number of Funding Instances
10.1.2. Analysis by Amount Invested
10.1.3. Analysis by Type of Funding
10.1.4. Most Active Players: Analysis by Amount Raised
10.1.5. Most Active Investors: Analysis by Number of Instances
10.1.6. Analysis by Geography

11. KEY COMMERCIALIZATION STRATEGIES
11.1. Successful Drug Launch Strategy: ROOTS Framework
11.2. Successful Drug Launch Strategy: Product Differentiation
11.3. Commonly Adopted Commercialization Strategies based on the Development Stage of the Product
11.4. Key Commercialization Strategies Adopted by Companies Focused on RAS Targeting Therapies
11.4.1. Strategies Adopted Before Therapy Approval
11.5. Strategies Adopted During / Post Therapy Approval
11.6. Analysis by Ease of Implementation, Value Addition and Current Adoption (Harvey Ball Framework)

12. MARKET SIZING AND OPPORTUNITY ANALYSIS
12.1. Forecast Methodology and Key Assumptions
12.2. Global RAS Targeting Therapies Market, 2021-2031
12.3. Global RAS Targeting Therapies Market, 2021-2031: Distribution by Target Indication
12.4. Global RAS Targeting Therapies Market, 2021-2031: Distribution by Type of Molecule
12.5. Global RAS Targeting Therapies Market, 2021-2031: Distribution by Type of Therapy
12.6. Global RAS Targeting Therapies Market, 2021-2031: Distribution by Route of Administration
12.7. Global RAS Targeting Therapies Market, 2021-2031: Distribution by Geography
12.8. RAS Targeting Therapies: Individual Product Sales Forecasts
12.8.1. LUMAKRASTM (Amgen): Sales Forecast
12.8.2. Adagrasib (Mirati Therapeutics): Sales Forecast
12.8.3. AMO-01 (AMO Pharma): Sales Forecast
12.8.4. Antroquinonol (Golden Biotech): Sales Forecast
12.8.5. Binimetinib (Array Biopharma): Sales Forecast
12.8.6. CH7126766/VS6766 (Verastem Oncology): Sales Forecast
12.8.7. LXH274 (Novartis): Sales Forecast
12.8.8. Rigosertib (Onconova Therapeutics): Sales Forecast
12.8.9. RMC-4630 (Revolution Medicine): Sales Forecast
12.8.10. TG01 (Targovax): Sales Forecast
12.8.11. Tipifarnib (Kura Oncology): Sales Forecast
12.8.12. siG12D (Silenseed): Sales Forecast

13. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS